ReproNovo

Executive Summary

ReproNovo is a clinical-stage biopharmaceutical company headquartered in Basel, Switzerland, dedicated to developing innovative therapies for reproductive medicine and women's health. Founded in 2017, the company addresses unmet needs in male and female infertility and conditions such as adenomyosis. Its lead candidate, RPN-001, is an oral small molecule currently in Phase 2 trials for male infertility, representing a potential first-in-class treatment targeting a large market with limited therapeutic options. ReproNovo leverages deep expertise in reproductive biology to build a pipeline that could transform fertility care globally. RPN-001's Phase 2 trial is expected to yield interim efficacy and safety data in late 2026, which will be a critical milestone for the program. Positive results could support advancement to Phase 3 and attract partnership interest from larger pharmaceutical companies seeking to expand into reproductive health. The company also has preclinical programs for adenomyosis and other indications, though these are earlier stage. With a focused strategy and a leadership team experienced in drug development and reproductive medicine, ReproNovo is positioned to create significant value in a niche but growing therapeutic area.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Interim Data Readout for RPN-001 in Male Infertility60% success
• Q2 2027Partnership or Licensing Deal for RPN-00140% success